The decision comes as the company is discontinuing clinical testing of a CLDN6-targeted CAR T-cell therapy in testicular cancer.

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Researchers mapped Y chromosome loss across thousands of individual cells from human cancers, with disturbing results.

Yoseph Williamson, a Colorado Springs teen, is living with a rare genetic disorder that causes painful tumors on his nerve ...

At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...

A South Korean research team has accomplished what was once thought of as science fiction: reprogramming malignant cancer ...

Justin Taylor, M.D., a physician-scientist at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...

Lola, a golden retriever with a unique and powerful bond with her owner, Allison Roth, is living proof of resilience and the ...

USC researchers are exploring how electric fields, combined with immunotherapy and chemotherapy, could extend survival for ...

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a ...

Cancer researchers have a multitude of tools to study tumors. Histological staining uses dyes to make different kinds of ...